Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
Listen to Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss their thoughts on what to know about managing toxicities associated with FGFR inhibitors in the treatment of urothelial cancer and other malignancies.
Decera Clinical Education Oncology Podcast · Ignacio Durán MD PhD, Alison Birtle MD FRCP FRCR
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies
Presenters:
Ignacio Durán, MD, PhD
Associate Professor
GU Oncology Program Leader
Department of Medical Oncology
Hospital Universitario Marques de Valdecilla-Idival
Santander, Spain
Alison Birtle, MD, FRCP, FRCR
Honorary Senior Lecturer
Faculty of Health and Medicine
University of Manchester
Manchester, United Kingdom
Consultant Oncologist
Rosemere Cancer Centre
Lancashire Teaching Hospitals
Preston, Lancashire, United Kingdom
Content based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.
Link to full program:
http://bit.ly/3cf28jH
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.